KOWA Research Institute Study: A Phase 3, prospective, double-masked, randomized, multi-center, vehicle-controlled, parallel-group, 12-week administration and 40 – week extension study confirming the efficacy and safety of K-161 Ophthalmic Solution for the treatment of moderate to severe dry eye disease.
Click here for more information.
B&L Pediatric Study: A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy Adult Subjects and in Pediatric Subjects with a History or Family History of Atopic Disease (including Allergic Conjunctivitis)
Click here for more information.